Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 347

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 347
---
 $0.6 million and $0.4 million for the three months ended June 30, 2025 and 2024, respectively, and to $1.3 million and $2.1 million for the six months ended June 30, 2025 and 2024, respectively. Realized foreign exchange losses amounted to $0.3 million and $0.7 million for the three and six months ended June 30, 2025, and were not material for the three and six months ended June 30, 2024.Net Loss Per ShareBasic net loss per share is computed by dividing net loss by the weighted-average shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. Diluted net loss per share excludes the potential impact of the Company’s common stock subject to repurchase, common stock options, restricted stock units, contingently issuable employee stock purchase plan shares and common stock issuable upon conversion of convertible notes because their effect would be anti-dilutive due to the Company’s net loss. Basic and diluted net loss per share were the same for the three and six months ended June 30, 2025 and 2024.The following outstanding potential dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: As of June 30,  20252024Options to purchase common stock and restricted stock units12,477,63612,182,480Common stock issuable upon conversion of convertible notes9,963,9639,964,247Employee stock purchase plan contingently issuable25,09927,086Total22,466,69822,173,813Recent Accounting Pronouncements Not Yet AdoptedFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the accompanying unaudited condensed consolidated financial statements and disclosures.In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU